Product Images Yeztugo

This text indicates the availability of components for single-use, including syringes with withdrawal and injection needles of specific sizes: 18G, 1% inch and 226, %h inch. The mention of "2 x2 x2" may refer to the quantity or stock number.*

This text provides instructions for preparing vial and syringe for injection. It includes details on using a 22G injection needle, expelling air bubbles, selecting and cleaning an injection site, administering subcutaneously, and repeating the steps for a second injection. Additionally, it highlights the importance of ensuring the withdrawal needle is correctly attached, the solution in the syringe is clear with no particles, and the product is not expired. The recommended injection sites are at least 2 inches from the navel, with a 50° angle preferred.*

This text provides information about Yeztugo tablets, each containing 300 mg of lenacapavir sodium. The tablets should be stored between 20°C-25°C (68°F-77°F) with excursions permitted between 15°C-30°C (59°F-86°F). The recommended dosage should be discussed with a healthcare provider, and the tablets should only be dispensed in their original container. It is important to keep the tablets out of reach of children. The tablets are manufactured for Gilead Sciences, Inc., and the healthcare provider will provide guidance on when to take the tablets.*

This is a description of Yeztugo (lenacapavir) injection, with a concentration of 463.5 mg/1.5 mL. The packaging contains 2x 1.5 mL lenacapavir single-dose vials, 2 withdrawal needles (18 gauge, 1% inch), 2 syringes, and 2 injection needles (22 gauge, % inch). To receive the full 927 mg dose, both vials must be administered. The product is for subcutaneous injection and is for administration by healthcare professionals only. The package also includes prescribing information, instructions for use, and patient information. Developed by GILEAD.*